Leerink Partnrs Issues Positive Estimate for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of Vertex Pharmaceuticals in a report issued on Tuesday, May 6th. Leerink Partnrs analyst D. Risinger now forecasts that the pharmaceutical company will earn $3.78 per share for the quarter, up from their prior estimate of $3.58. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Leerink Partnrs also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $4.28 EPS, Q4 2025 earnings at $4.70 EPS, FY2025 earnings at $16.24 EPS and FY2026 earnings at $17.60 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the prior year, the business posted $4.76 EPS. The business’s revenue was up 2.6% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on VRTX. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 6th. Scotiabank lowered their price target on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating for the company in a report on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Wolfe Research downgraded Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. Thirteen investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $425.30 on Friday. The company has a market capitalization of $109.22 billion, a price-to-earnings ratio of -193.32, a PEG ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The business has a 50-day moving average of $488.74 and a 200-day moving average of $465.87.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brown Lisle Cummings Inc. acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Mascagni Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $31,000. Sugar Maple Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $35,000. Golden State Wealth Management LLC bought a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, SJS Investment Consulting Inc. increased its holdings in shares of Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after buying an additional 30 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares in the company, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Altshuler sold 3,231 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This trade represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,315 shares of company stock valued at $2,121,012. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.